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ABSTRACT 
 
Background: MicroRNA (miRNA) is non coding-RNA that comprises 18-22 nucleotides. miRNA 
binds its gene targets in the 3'-untranslated region (3'-UTR), causing direct degradation of mRNA 
and repressed translationof RNA. MicroRNA regulates various biological processes, including cell 
proliferation, apoptosis, cell growth, cell differentiation, and metabolism. Various changes have 
been identified miRNA expression in different types of cancers. This study aimed to describe the 
expression of miR-155 in patients with breast cancer tissue in Haji Adam Malik Hospital in Medan. 
Subjects and Method: This was a descriptive study. A total sample was 64 paraffin tissue blocks 
was taken from female patients with breast cancer at the surgical oncology unit, Haji Adam Malik 
Hospital in 2013-2014. RNA sample were isolated and checked using a spectrophotometer followed 
by cDNA synthesis. Then this sample was analyzed for miR-155 expression by using Real Time 
qPCR. Histopathological grade data were obtained from the medical record. 
Results: The miR-155 expression in the breast cancer patients is higher than  that in the UniSp6 
RNA Spike-in (internal controls). miR-155 expression was 29.64, 28.44, 29.22, in grade-I, grade-II, 
grade-III breast cancer, respectively. UniSp6 RNA Spike-in was 22.30, 22.89, 23.10, respectively in 
the control groups. Thus, increase in miR-155 expression was the highest in grade I breast cancer 
patients. 
Conclusion: Increased miR-155 expression can be used as a biomarker for early diagnosis and 
prognosis of breast cancer. 
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BACKGROUND 
 
Cancer is the third leading cause of death 
worldwide after cardiovascular diseases 
and infections (Hauptman and Glavac, 
2013). Breast cancer is the second highest 
incidence in women worldwide having ova-
rian cancer and about 7% -10% of all malig-
nant tumors. It is estimated that worldwide 
more than 508,000 women die in 2011 
from breast cancer, because most women 
with breast cancer diagnosed at advanced 
stages of the disease because early symp-
toms are not typical (WHO, 2013; Zhao et 
al., 2012). 
Screening for breast cancer allows 
early diagnosis and potentially reduce mor-
tality. Currently palpation is a tool most re-
liable screening for breast cancer (Zhao et 
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al., 2012). Although today much research 
done right look for biomarkers as a diag-
nostic tool and prognostic cancer, but still 
have not found an effective early detection 
techniques in order to reduce the number 
of deaths due to cancer (Hauptman and 
Glavac, 2013). 
Grade histopathology, consisting of 
grade I, II, and III, the morphological 
assessment of the degree of differentiation 
of cancer tissue, which can be used to 
provide diagnostic and prognostic infor-
mation in breast cancer (Tavassoli and 
Devilee, 2003; Dağlar et al., 2010). Histo-
pathological examination method is a me-
thod of diagnosing breast cancer terper-
cayadalam of breast lesions, but it depends 
on how the sampling and readability of the 
results by an expert pathology (Oakley and 
going, 1995). Therefore, the validity of test 
results is still subjective. Therefore, it re-
quired continuous efforts to obtain more 
objective biomarker, sensitive and specific. 
One potential candidate cancer biomarkers 
in the future that has been researched lately 
is a miRNA. 
Micro RNA are non coding-RNA that 
consists of about 18-22 nucleotides, which 
is transcribed from the intergenic regions of 
the genome and the genie who is a new 
gene regulator (Rodriguez et al., 2004). 
MicroRNA bind its gene targets in the 3'-
untranslated region (3'- UTR), causing 
direct mRNA degradation or translational 
repression of mRNA (Valencia-Sanchez et 
al., 2006; Huntzinger and Izaurralde, 
2011). MicroRNA is very stable, the tissue 
samples were preserved, even several years 
after formaline fixation and embedded in 
paraffin, and efficiently extracted from the 
specimen and is measured in (Lu et al., 
2012; Szafranska et al., 2008). 
MicroRNA has been implicated in the 
regulation of a wide spectrum of biological 
processes, including cell proliferation, apop-
tosis, growth, differentiation and meta-
bolism. Various changes have been iden-
tified miRNA expression in different types 
of human cancer. In 2005, miRNA ex-
pression levels in 76 primary breast cancer 
tissues and 10 normal tissues using mi-
croarray analysis. They found changes in 
the regulation of miR-10b, miR-125b, miR-
145, miR-21 and miR-155 are the most 
significant. 
The cancer tissue studies conducted 
by Volinia (2006) using significance analy-
sis of microarrays (SAM) and predictive 
analysis of microarrays (PAM) were obtain-
ed from six different types of solid tumor 
miR-21 and miR-155 as a top onkomiR 
(miRNA as a biomarker of poor prognosis). 
From the many miRNA are experiencing a 
change of regulation in breast cancer, the 
researchers chose miR-155 because it is 
based on the results research Mar-Aguilar 
(2013), proved that the expression of miR-
145 and miR-155 are the most sensitive and 
specific for breast cancer. From the results 
of the study found the diagnostic test 
efficiency were 85.7% for miR-10b, miR-
89.3% for 21.89% for miR-125b, miR-
96.4% for 145.96% for miR -155.78% for 
miR-191. 
The research question of this study: 
what is the miR-155 expression in grade-I, 
grade-II, grade-III breast cancer, in compa-
rison with the control group (UniSp6 RNA 
Spike-in)? 
 
SUBJECTS AND METHOD 
This was a descriptive study. Samples were 
64 paraffin blocks of female patients with 
breast cancer tissue in surgical oncology at 
Adam Malik Hospital in 2013-2014. It was 
taken from the bank block Anatomical 
Pathology Laboratory of Dr H. Adam Malik 
who met the inclusion criteria and obtained 
by purposive sampling. 
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Samples were first sliced paraffin 
blocks as much as 2-4 slices, and then to 
isolate total RNA, then check the quality 
and quantity of the isolated RNA using a 
NanoDrop spectrophotometer. CDNA syn-
thesis is then performed using RT-PCR. 
Quantification analysis of miR-155 used 
Real Time qPCR to get value ExiLent Cq 
using SYBR Green master mix, primer sets 
of miR-155 (HSA-miR-155-5p), spike un-
controlled primer set (UniSp6 RNA spike-
ins). This study was approved by the Health 
Research Ethics Committee of the Faculty 
of Medicine University of North Sumatra. 
 
RESULTS 
 
Table 1. Characteristics of research 
subjects 
Characteristics (n) Total 
Age   
30-49 36 
50-78 28 
Histopathology Grade   
      Grade I 15 
      Grade II 38 
      Grade III 11 
 
Characteristics of research subjects 
are presented in Table 1, whereas the ex-
pression of miR-155 image with UniSp6 
RNA Spike-in (as internal control) in breast 
cancer tissue (value cq) is presented in 
Figure 1. 
In this study, most patients are aged ≤ 
49 years and is in line with research Wang 
(2010) which is the subject of research they 
are also more aged <48 years. Breast cancer 
affects more and more by young women, 
this is one of them caused by mutations in 
the genes BRCA1 and BRCA2 that increases 
the incidence of breast cancer is familial 
approximately 45% and of the familial.  
The incidence of breast cancer in 
early-onset increased by approximately 80% 
(Mattiske et al., 2012; Miki et al., 1994). In 
addition, the menstrual ages ranging from 
early (<13 years) and / or experienced me-
nopause older (≥55 years) had a higher risk 
of developing breast cancer (Kumar et al., 
2007; Department of Health Affairs, 2009). 
The increased risk caused by the longer 
lifetime exposure to the hormones estrogen 
and progesterone (Tryggvadottir et al., 
2003; Wrensch et al., 2003; Ostad and 
Parsa, 2011). Hormon estrogen and proges-
terone can trigger the proliferation of 
breast epithelial cells to become cancerous 
(Anderson, 2002) 
Wang et al., (2010) and Lu et al., 
(2012), states the dominant subject of their 
study on grade II and III. Most women with 
breast cancer diagnosed at advanced stages 
of the disease because early symptoms are 
not typical (Zhao et al., 2012). 
Based on Figure 1, we can see the 
results of the paraffin blocks of breast 
tissue of women with breast cancer found 
an increased expression of miR-155 in all of 
the study subjects either grade I, grade II 
and grade III compared with UniSp6 
internal controls.  
 
 
 
a
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Figure 1. (a) Real Time qPCR quantification of miR-155 and UniSp6 RNA Spike-in  
(as internal control) -Value cq, (b) Melt Peak miR-155 and UniSp6 RNA Spike-in,  
(c) Melt Curve Mirza 155 and UniSp6 RNA Spike-in, (d) Expression of miR-155  
with UniSp6 RNA Spike-in on breast cancer tissue (value Cq) 
 
DISCUSSION 
 
The results of this study are consistent with 
those of Lu (2012). Lu’s study identifies 
miR-155 expression using the Real Time 
qPCR.In the Lu study, miR-155 expression 
was 5-times higher in breast cancer than 
that in normal breast tissue, and it was 
statistically significant (p <0.05). 
Likewise, the miR-155 expression was 
5-6 times higher in the plasma of breast 
cancer than that in normal female plasma, 
and it was statistically significant (p<0.05). 
This finding is also consistent with 
that of one Wang (2010). In Wang’s study, 
the miR-155 expression was higher in both 
tissue sample and blood sample in patients 
with benign breast tumors,  grade II, and 
grade III breast cancer patients, than that 
of normal controls, and it was statistically 
significant (p <0.05).  
Grade I Grade II Grade III
UniSp6 22.30 22.89 23.10
miR-155 29.64 28.44 29.22
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From the study it was also found a 
strong correlation (r=0.85) between the 
miR-155expression in tissue and serum. 
In another study conducted by Mar-
Aguilar (2013), it was also found that 
themiR-155expression in the serum of 
breast cancer patients was significantly 
higher than the miR-155 expression in the 
serum of normal women, and it was 
statistically significant (p <0.001).  
This study also found that miR-155 
expression had high sensitivity (94.40%) 
and high spesificity (100%) when compared 
with the gold standard histopatology 
assessment. This means that the false 
negative rate is very low, while the false 
positive rate is zero.The efficiency of miR-
155 expressionas diagnostic test was high 
(96.4%). 
This findings further reaffirm that the  
miR-155 expression in serum reflects the 
condition of the miR-155 expression in the 
network. Further, this findings confirm that  
the examination of serum miR-155 as a 
diagnostic method is minimally invasive 
and accurate. 
These results support the miR-155 
expression as a potential biomarker for 
early detection, early diagnosis, and prog-
nosis of breast cancer. But further  studies 
are needed to provide more evidence. 
This study found that themiR-155 
expression on the whole network of breast 
cancer patients is higher than that of 
UniSp6 RNA Spike-in (i.e. internal con-
trols). In particular, the miR-155 expression 
were highest in grade I breast cancer 
patients. 
The researchers of the current study 
suggest that further studies be conducted to 
compare the miR-155 expression in tissues 
and serum of patients with benign breast 
tumor, grade I, II, and III breast cancer,and 
with different histopatologyc  types (ductal 
and lobular types). 
Research in miR-155 expression can 
be used to develop an accurate and less 
invasive peripheral blood-based biomarker 
for the detection, early diagnosis, and 
prognosis of breast cancer metastasis.  
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